AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15204675
Drug: Buprenorphine-naloxone taper
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine-naloxone taper regimen for short-term opioid detoxification
Trial: 15204675
Drug: Buprenorphine-naloxone taper
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine-naloxone taper regimen
Trial: 11556635
Drug: Mecamylamine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mecamylamine (2.5 to 7.5 mg/day)
Trial: 3027905
Drug: Lisinopril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (20 mg/d)
Trial: 3027905
Drug: Lisinopril plus
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril plus Hydrochlorothiazide (HCTZ)
Trial: 31581743
Drug: High green
RxNorm normalized name: acid green 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High green leafy vegetable (GLV) dietary intervention, one cooked cup equivalent daily for 4 weeks
Trial: 28213170
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Mirtazapine + SSRIs)
Trial: 28213170
Drug: SSRIs monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRIs monotherapy
Trial: 21496149
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous (IV) insulin infusion
Trial: 19954075
Drug: Domestic split
RxNorm normalized name: domestic cow dander extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domestic split influenza virus vaccine (study group)
Trial: 19954075
Drug: Imported vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imported vaccine (control group 1)
Trial: 19954075
Drug: Imported vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imported vaccine (control group 2)
Trial: 14660311
Drug: Midazolam and
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam and topical lidocaine‐prilocaine cream (EMLA)
Trial: 14660311
Drug: Ketamine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine and topical placebo cream
Trial: 9211479
Drug: Capsaicin (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsaicin (0.03 mg/ml, 20 microliters applied topically for 30 min)
Trial: 20716255
Drug: Moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg once daily for 14 days
Trial: 20716255
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg once daily plus metronidazole 500 mg twice daily for 14 days
Trial: 2290163
Drug: Subacromial injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subacromial injection of triamcinolone
Trial: 2290163
Drug: Oral diclofenac
RxNorm normalized name: diclofenac Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diclofenac 50 mg TDS
Trial: 22086300
Drug: 40 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 μg vitamin D(3) plus 1,000 mg calcium per day
Trial: 22086300
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg calcium per day (Control)
Trial: 19292654
Drug: Bofu‐tsusho‐san (BTS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bofu‐tsusho‐san (BTS) 7.5 g/day
Trial: 19292654
Drug: Placebo of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of BTS 7.5 g/day
Trial: 19292654
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E 500 mg and Vitamin C 1000 mg/day
Trial: 11594439
Drug: Hydromorphone (1.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone (1.5, 3, and 6 mg/70 kg)
Trial: 11594439
Drug: Butorphanol (1.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol (1.5, 3, 6, and 12 mg/70 kg)
Trial: 184377
Drug: N 041
RxNorm normalized name: (Alginate)n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N 041 (essential phospholipids in combination with Clofibrate)
Trial: 23021878
Drug: Omalizumab (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab (4 to 8 subcutaneous doses, n = 16)
Trial: 19624838
Drug: Cineole 200
RxNorm normalized name: Cineole
DrugBank: Eucalyptol (DB03852)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cineole 200 mg, 3 times daily for 6 months
Trial: 17114212
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy (10 sessions over five weeks)
Trial: 9140801
Drug: moexipril 7.5
RxNorm normalized name: moexipril 7.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: moexipril 7.5 mg/HCTZ 12.5 mg
Trial: 9140801
Drug: metoprolol 100
RxNorm normalized name: metoprolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoprolol 100 mg/HCTZ 12.5 mg
Trial: 2142246
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg toremifene daily
Trial: 2142246
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg toremifene daily
Trial: 30558968
Drug: Chlorhexidine-impregnated gel
RxNorm normalized name: chlorhexidine Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine-impregnated gel dressing
Trial: 26506580
Drug: Cognitive-Behavioral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Therapy (CBT) delivered over 14 sessions for 4 months
Trial: 26506580
Drug: Control condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control condition consisting of written psycho-education materials and weekly telephone monitoring
Trial: 21846154
Drug: Aliskiren 150
RxNorm normalized name: aliskiren 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 150 mg (titrated to 300 mg after 6 weeks)
Trial: 19542517
Drug: 1SMS (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1SMS (one weekly SMS feedback)
Trial: 19542517
Drug: 3SMS (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3SMS (three weekly SMS feedbacks)
Trial: 17287682
Drug: Facilitated PCI
RxNorm normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facilitated PCI (immediate planned PCI after i.v. thrombolytic therapy)
Trial: 11527067
Drug: Qi therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qi therapy (QT)
Trial: 8840055
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml normal saline (Control Group P)
Trial: 31072566
Drug: Rivaroxaban 2.5
RxNorm normalized name: rivaroxaban 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 2.5 mg plus aspirin
Trial: 26831333
Drug: 1% linalool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% linalool inhalation
Trial: 25233668
Drug: Photoelectric combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photoelectric combined with musical treatment (group A)
Trial: 25233668
Drug: Placebo (starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (starch tablet, group C)
Trial: 17925627
Drug: Sexual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sexual therapy group (n=47)
Trial: 15756442
Drug: Irinotecan 125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 125 mg/m2, FA 20 mg/m2 followed by 5‐FU 500 mg/m2 bolus, weekly for 4 weeks (arm A)
Trial: 15756442
Drug: Irinotecan 350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 350 mg/m2 alternating with FA 20 mg/m2/day followed by 5‐FU bolus 425 mg/m2/day for 5 days (arm B)
Trial: 15756442
Drug: FA 20
RxNorm normalized name: INPEFA 200mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FA 20 mg/m2/day followed by 5‐FU bolus 425 mg/m2/day over 5 days every 4 weeks (arm C, Mayo Clinic regimen)
Trial: 8559001
Drug: Fordtran solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fordtran solution (polyethylene glycol solution)
Trial: 8559001
Drug: Ringer's solution
RxNorm normalized name: Ringer's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's solution (whole-gut lavage)
Trial: 7018164
Drug: Tinidazole 2
RxNorm normalized name: tinidazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole 2 g single oral dose given to females with treated partners
Trial: 19036903
Drug: nab-paclitaxel (260
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nab-paclitaxel (260 mg/m² q3wk)
Trial: 19036903
Drug: docetaxel (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: docetaxel (100 mg/m² q3wk)
Trial: 19036903
Drug: paclitaxel (175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: paclitaxel (175 mg/m² q3wk)
Trial: 15469651
Drug: DHA-rich oil
RxNorm normalized name: Ulkenia DHA oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-rich oil (4.9 g DHA/d)
Trial: 15469651
Drug: EPA-rich oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA-rich oil (4.8 g EPA/d)
Trial: 3555650
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with chlorambucil and prednisone (CP)
Trial: 29619838
Drug: L-homoarginine (L-hArg)
DrugBank: L-homoarginine (DB03974)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-homoarginine (L-hArg) levels
Trial: 25122097
Drug: Task-oriented therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Task-oriented therapy with personalized resistance (TOT_ST group)
Trial: 25122097
Drug: Task-oriented therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Task-oriented therapy without load (TOT group)
Trial: 22921881
Drug: Statin discontinuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin discontinuation
Trial: 20804498
Drug: Pralidoxime (700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pralidoxime (700 mg)
Trial: 20804498
Drug: Pralidoxime (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pralidoxime (350 mg), Atropine (2 mg), Avizafone (20 mg)
Trial: 15705641
Drug: Teicoplanin 400
RxNorm normalized name: Teicoplanin 400 mg powder for solution for injection vial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin 400 mg every 12 h
Trial: 7637721
Drug: Intravenous ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ganciclovir (5 mg/kg daily)
Trial: 7637721
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir (3000 mg daily)
Trial: 2692819
Drug: Naproxen (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (375 mg orally, twice daily)
Trial: 832528
Drug: Fosfomycin, total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosfomycin, total dose of 4 g (2g/4h)
Trial: 832528
Drug: Fosfomycin, single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosfomycin, single dose of 4 g (2 g in each buttock)
Trial: 832528
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 4 g (control for failures)
Trial: 29719302
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Bevacizumab (10 mg/kg IV every 14 days) and Erlotinib (150 mg orally daily)
Trial: 29719302
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Bevacizumab and Erlotinib
Trial: 29719302
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Bevacizumab and Erlotinib among Child‐Pugh class A patients
Trial: 12143912
Drug: Direct switch
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct switch to olanzapine (10 mg/day for 6 weeks)
Trial: 12143912
Drug: Start‐taper switch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Start‐taper switch to olanzapine (10 mg/day for 6 weeks) with decreasing doses of usual antipsychotic for first 2 weeks
Trial: 10201422
Drug: 60 mg/day
RxNorm normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/day mianserin
Trial: 2213394
Drug: Nebulized albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized albuterol (0.15 mg/kg/dose)
Trial: 468583
Drug: Subcutaneous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous heparin (3x5000 IU, starting 2 hours preoperatively)
Trial: 468583
Drug: Intravenous dextran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dextran (3x500 ml of 6% dextran 70)
Trial: 24069230
Drug: Opal-HIV-Gag(c) 12
RxNorm normalized name: carbetapentane tannate / chlorpheniramine tannate Oral Suspension [C-Tanna 12]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opal-HIV-Gag(c) 12 mg
Trial: 24069230
Drug: Opal-HIV-Gag(c) 24
RxNorm normalized name: C.i. solvent red 24
DrugBank: Scarlet red (DB19136)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opal-HIV-Gag(c) 24 mg
Trial: 24069230
Drug: Opal-HIV-Gag(c) 48
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opal-HIV-Gag(c) 48 mg
Trial: 21840601
Drug: Tacrolimus 0.5
RxNorm normalized name: tacrolimus 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus 0.5 mg capsules
Trial: 21840601
Drug: Tacrolimus 5
RxNorm normalized name: tacrolimus 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus 5 mg capsules
Trial: 21840601
Drug: Tacrolimus test
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus test formulations
Trial: 19150378
Drug: Neonatal 7-valent
RxNorm normalized name: calcium acetate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neonatal 7-valent pneumococcal conjugate vaccine (7vPCV)
Trial: 18044435
Drug: One dose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose, vaccinated once at reimplant (day 42)
Trial: 18044435
Drug: Two doses,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses, vaccinated on arrival (day 0) and again at reimplant (day 42)
Trial: 18044435
Drug: Three doses,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses, vaccinated on arrival (day 0), on day 21, and again at reimplant (day 42)
Trial: 9872488
Drug: Nifedipine (30‐60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (30‐60 mg/day) for mild to moderate hypertension for at least 1 year
Trial: 23542611
Drug: 360 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 360 mg/m2 epratuzumab
Trial: 23542611
Drug: 720 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 720 mg/m2 epratuzumab
Trial: 23542611
Drug: 360 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 360 mg/m2 epratuzumab in SL0006
Trial: 11337625
Drug: Methylprednisolone and
RxNorm normalized name: methylprednisolone and antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone and bupivacaine combination
Trial: 3310586
Drug: Moricizine HCl
RxNorm normalized name: moricizine HCl
DrugBank: Moricizine (DB00680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moricizine HCl (816 ± 103 mg daily)
Trial: 3310586
Drug: Moricizine HCl
RxNorm normalized name: moricizine HCl
DrugBank: Moricizine (DB00680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moricizine HCl (800 mg daily)
Trial: 3310586
Drug: Disopyramide (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disopyramide (600 mg daily)
Trial: 29895491
Drug: Silymarin 140
RxNorm normalized name: silymarin 140 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin 140 mg, thrice daily for 45 days
Trial: 28539413
Drug: Unconditional cash
RxNorm normalized name: Cashew
DrugBank: Cashew (DB10653)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unconditional cash transfers (UCT) of 10,000 West African Financial Community of Africa francs (∼US$17) provided monthly from July to November over 2 years (2013 and 2014).
Trial: 12690216
Drug: Dexmedetomidine (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (target plasma level 0.4 ng/mL)
Trial: 12690216
Drug: Meperidine (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine (target plasma level 0.3 microg/mL)
Trial: 12690216
Drug: Meperidine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine plus dexmedetomidine (target plasma levels of 0.3 microg/mL and 0.4 ng/mL)
Trial: 29171139
Drug: linagliptin 1
RxNorm normalized name: empagliflozin-linagliptin 10 mg-5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: linagliptin 1 mg
Trial: 27643296
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg + Amlodipine 5 mg (L/A group)
Trial: 27643296
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg + Hydrochlorothiazide 12.5 mg (L/H group)
Trial: 27643296
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg + Amlodipine 100 mg (L/A group)
Trial: 27643296
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg + Hydrochlorothiazide 100 mg (L/H group)
Trial: 18762494
Drug: Nicotine nasal
RxNorm normalized name: nicotine Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine nasal spray with counseling for 8 weeks
Trial: 18762494
Drug: Weekly counseling
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly counseling alone for 8 weeks
Trial: 15983465
Drug: Alfentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil infusion (30-min duration)
Trial: 15983465
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion (30-min duration)
Trial: 7049584
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg acebutolol alone
Trial: 7049584
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg acebutolol + hydrochlorothiazide/amiloride diuretic
Trial: 7049584
Drug: hydrochlorothiazide/amiloride diuretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydrochlorothiazide/amiloride diuretic
Trial: 21424274
Drug: Level run
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Level run (L)
Trial: 14685830
Drug: NON OP
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NON OP (non-operative therapy)
Trial: 7307591
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no indomethacin therapy)
Trial: 31627746
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and surgery
Trial: 30651130
Drug: Trans-tympanic injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trans-tympanic injection of sodium thiosulfate gel in the left or right ear
Trial: 30651130
Drug: Control ears
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control ears (no treatment)
Trial: 28340430
Drug: Bilateral sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral sequential stimulation (BSS) with theta burst stimulation (TBS)
Trial: 24856433
Drug: Early oral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early oral feeding (after 2 hours)
Trial: 24856433
Drug: Conventional oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oral feeding (after 18 hours)
Trial: 22612913
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy and exercises (N = 33)
Trial: 19528286
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg PA-824
Trial: 19528286
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg PA-824
Trial: 14674937
Drug: Allergen specific
RxNorm normalized name: Allergen specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergen specific immunotherapy (SIT) with standardized birch pollen extract
Trial: 7646570
Drug: Quinidine sulphate
RxNorm normalized name: Quinidine sulphate
DrugBank: Quinidine (DB00908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinidine sulphate 250 mg administered at 10:00 h
Trial: 7646570
Drug: Quinidine sulphate
RxNorm normalized name: Quinidine sulphate
DrugBank: Quinidine (DB00908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinidine sulphate 250 mg administered at 22:00 h
Trial: 28514527
Drug: Robenacoxib (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robenacoxib (2.0 mg/kg SC injection prior to surgery and for 2 additional days postoperatively)
Trial: 28514527
Drug: Placebo (SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (SC injection prior to surgery and for 2 additional days postoperatively)